The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Topiramate for Migraine Prevention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Abstract
CONTEXT: Small open-label and controlled trials suggest that the antiepileptic drug topiramate is effective for migraine prevention. OBJECTIVE: To assess the efficacy and safety of topiramate for migraine prevention in a large controlled trial. DESIGN, SETTING, AND PATIENTS: A 26-week, randomized, double-blind, placebo-controlled study was conducted during outpatient treatment at 52 North American clinical centers. Patients were aged 12 to 65 years and had a 6-month history of migraine (International Headache Society criteria) and 3 to 12 migraines a month but no more than 15 headache days a month during a 28-day prospective baseline phase. INTERVENTIONS: After a washout period, patients meeting entry criteria were randomized to topiramate (50, 100, or 200 mg/d) or placebo. Topiramate was titrated by 25 mg/wk for 8 weeks to the assigned or maximum tolerated dose, whichever was less. Patients continued receiving that dose for 18 weeks. MAIN OUTCOME MEASURES: The primary efficacy measure was change from baseline in mean monthly migraine frequency. Secondary efficacy measures included responder rate (proportion of patients with > or =50% reduction in monthly migraine frequency), reductions in mean number of monthly migraine days, severity, duration, and days a month requiring rescue medication, and adverse events. The month of onset of preventive treatment action was assessed. RESULTS: Of 483 patients randomized, 468 provided at least 1 postbaseline efficacy assessment and comprised the intent-to-treat population. Mean monthly migraine frequency decreased significantly for patients receiving topiramate at 100 mg/d (-2.1, P =.008) and topiramate at 200 mg/d (-2.4, P<.001) vs placebo (-1.1). Statistically significant reductions (P<.05) occurred within the first month with topiramate at 100 and 200 mg/d. The responder rate was significantly greater with topiramate at 50 mg/d (39%, P =.01), 100 mg/d (49%, P<.001), and 200 mg/d (47%, P<.001) vs placebo (23%). Reductions in migraine days were significant for the 100-mg/d (P =.003) and 200-mg/d (P<.001) topiramate groups. Rescue medication use was reduced in the 100-mg/d (P =.01) and 200-mg/d (P =.005) topiramate groups. Adverse events resulting in discontinuation in the topiramate groups included paresthesia, fatigue, and nausea. CONCLUSION: Topiramate showed significant efficacy in migraine prevention within the first month of treatment, an effect maintained for the duration of the double-blind phase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Burden of Migraine in the United States: Data From the American Migraine Study II
Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001) · Headache: The Journal of Head and Face Pain · doi:10.1046/j.1526-4610.2001.041007646.x · Cited by 2,268
Silberstein, S. D. (2000) · Neurology · doi:10.1212/wnl.55.6.754 · Cited by 1,360
Burden of Migraine in the United States: Disability and Economic Costs
Hu, X. H., Markson, L. E., Lipton, R. B., Stewart, W. F., & Berger, M. L. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.8.813 · Cited by 910
Shank, R. P., Gardocki, J. F., Streeter, A. J., & Maryanoff, B. E. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb02163.x · Cited by 810
Guidelines for Controlled Trials of Drugs in Migraine: Second Edition
International Headache Society Clinical Trials Subcommittee, Tfelt-Hansen, P., Block, G., Dahlöf, C., Diener, H.-C., Ferrari, M., Goadsby, P., Guidetti, V, Jones, B., Lipton, R., et al. (2000) · Cephalalgia · doi:10.1046/j.1468-2982.2000.00117.x · Cited by 698
Testing the Statistical Certainty of a Response to Increasing Doses of a Drug
Tukey, J. W., Ciminera, J. L., & Heyse, J. F. (1985) · Biometrics · doi:10.2307/2530666 · Cited by 486
McElroy, S. L., Arnold, L. M., Shapira, N. A., Keck, P. E., Rosenthal, N. R., Karim, M. R., Kamin, M., & Hudson, J. I. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.255 · Cited by 484
Migraine, quality of life, and depression: A population-based case–control study
Lipton, R. B., Hamelsky, S. W., Kolodner, K. B., Steiner, T. J., & Stewart, W. F. (2000) · Neurology · doi:10.1212/wnl.55.5.629 · Cited by 479
Migraine prevalence. A review of population-based studies.
Stewart, W. F., Shechter, A. L., & Rasmussen, B. (1994) · PubMed · Cited by 416
Features of medication overuse headache following overuse of different acute headache drugs
Limmroth, V., Katsarava, Z., Fritsche, G., Przywara, S., & Diener, H.-C. (2002) · Neurology · doi:10.1212/wnl.59.7.1011 · Cited by 391
Tronvik, E., Stovner, L. J., Helde, G., Sand, T., & Bovim, G. (2003) · JAMA · doi:10.1001/jama.289.1.65 · Cited by 355
The impact of migraine on quality of life in the general population: The GEM study
Terwindt, G. M., Ferrari, M. D., Tijhuis, M., Groenen, S. M. A., Picavet, H. S. J., & Launer, L. J. (2000) · Neurology · doi:10.1212/wnl.55.5.624 · Cited by 330
Migraine Prophylaxis With Divalproex
Mathew, N. T., Saper, J. R., Silberstein, S. D., Rankin, L., Markley, H. G., Solomon, S., Rapoport, A. M., Silber, C. J., & Deaton, R. L. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540270077022 · Cited by 329
Divalproex Sodium in Migraine Prophylaxis: A Dose-Controlled Study
Klapper, J., & on behalf of the Divalproex Sodium in Migraine Prophylaxis Study Group (1997) · Cephalalgia · doi:10.1046/j.1468-2982.1997.1702103.x · Cited by 280
A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis
Freitag, F. G., Collins, S. D., Carlson, H. A., Goldstein, J., Saper, J., Silberstein, S., Mathew, N., Winner, P. K., Deaton, R., & Sommerville, K. (2002) · Neurology · doi:10.1212/wnl.58.11.1652 · Cited by 274
Prevalence and clinical characteristics of migraine in France
Henry, P., Auray, J. P., Gaudin, A. F., Dartigues, J. F., Duru, G., Lantéri–Minet, M., Lucas, C., Pradalier, A., Chazot, G., & El Hasnaoui, A. (2002) · Neurology · doi:10.1212/wnl.59.2.232 · Cited by 270
Hoopes, S. P., Reimherr, F. W., Hedges, D. W., Rosenthal, N. R., Kamin, M., Karim, R., Capece, J. A., & Karvois, D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1109 · Cited by 211
Guidelines for Controlled Trials of Drugs in Migraine. First Edition
(1991) · Cephalalgia · doi:10.1046/j.1468-2982.1991.1101001.x · Cited by 189
Ziegler, D. K. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520170016015 · Cited by 136
A double-blind placebo-controlled trial of topiramate treatment for essential tremor
Connor, G. S. (2002) · Neurology · doi:10.1212/wnl.59.1.132 · Cited by 132
Diener, H., Matías‐Guiu, J., Hartung, E., Pfaffenrath, V., Ludin, H. P., Nappi, G., de Beukelaar, F., & on behalf of the Study Group (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.t01-1-00309.x · Cited by 116
DOUBLE BLIND STUDY OF PROPRANOLOL FOR MIGRAINE PROPHYLAXIS
Diamond, S., & Medina, J. L. (1976) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.1976.hed1601024.x · Cited by 103
Comparison of the Efficacy and Safety of Flunarizine to Propranolol in the Prophylaxis of Migraine
Gawel, M. J., Kreeft, J. H., Nelson, R. F., Simard, D., & Arnott, W. S. (1992) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100041962 · Cited by 72
Global Trends in Migraine Care
Brandes, J. L. (2002) · CNS Drugs · doi:10.2165/00023210-200216001-00003 · Cited by 70
Self-citationLong-Acting Propranolol in Migraine Prophylaxis: Results of a Double-Blind, Placebo-Controlled Study
Pradalier, A., Serratrice, G., Collard, M., Hirsch, É., Fève, J. R., Masson, M., Masson, C., Dry, J., Koulikovsky, G., Nguyen, G.-T., et al. (1989) · Cephalalgia · doi:10.1046/j.1468-2982.1989.0904247.x · Cited by 65
Topiramate: A Case Series Study in Migraine Prophylaxis
Young, W., Hopkins, M., Shechter, A. L., & Silberstein, S. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00380.x · Cited by 58
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
Cited by
Silberstein, S. D., Holland, S., Freitag, F., Dodick, D. W., Argoff, C., & Ashman, E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182535d20 · Cited by 897
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
Acupuncture for Patients With Migraine: A Randomized Controlled Trial
Linde, K., Streng, A., Jürgens, S., Hoppe, A., Brinkhaus, B., Witt, C., Wagenpfeil, S., Pfaffenrath, V., Hammes, M. G., Weidenhammer, W., et al. (2005) · JAMA · doi:10.1001/jama.293.17.2118 · Cited by 637
Chronic migraine: risk factors, mechanisms and treatment
May, A., & Schulte, L. H. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.93 · Cited by 630
Suppression of cortical spreading depression in migraine prophylaxis
Ayata, C., Jin, H., Kudo, C., Dalkara, T., & Moskowitz, M. A. (2006) · Annals of Neurology · doi:10.1002/ana.20778 · Cited by 570
Metadata
- Authors
- Brandes, J. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2004-02-25
- Volume
- 291
- Issue
- 8
- Pages
- 965
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2062526596
- Cited by
- 653
- References
- 28
- FWCI
- 38.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.